# PT-141 (Bremelanotide)

> Melanocortin agonist researched for sexual desire and arousal.

Source: https://peptides.cafe/peptide/pt-141
Category: Sexual Health · Neurologic
Tag: Libido

## Mechanism
A synthetic analog of α-MSH that activates melanocortin receptors (primarily MC4R) in the central nervous system. Unlike PDE5 inhibitors, it acts on neural pathways governing sexual desire rather than vascular flow.

## Research areas
- Hypoactive sexual desire disorder (FDA-approved as Vyleesi in premenopausal women)
- Male erectile response (research)
- Central arousal pathways

## Common research protocols
- On-demand subcutaneous use: Single subcutaneous dose approximately 45 minutes before anticipated activity in approved indication.

## Study summaries
- "Bremelanotide for hypoactive sexual desire disorder" — Obstetrics & Gynecology (2019): Phase 3 RECONNECT trials supporting FDA approval.

## Considerations
- FDA-approved (Vyleesi) only for HSDD in premenopausal women.
- Can cause nausea, flushing, transient blood pressure increases.
- Avoid in uncontrolled hypertension or cardiovascular disease.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.